Lexicon Pharmaceuticals announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana. The "Time to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF" post hoc analysis examined the timing of clinical benefit of sotagliflozin, defined as the first day post randomization when the hazard ratio for risk for the primary outcome of total number of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure was statistically significant and remained significant throughout follow up. A subgroup analysis was also conducted in patients with left ventricular ejection fraction less than 50% or greater than or equal to 50%. The analysis showed a statistically significant reduction in the risk for the primary outcome on Day 27, or time to clinical benefit of 27 days, in patients with worsening heart failure treated with sotagliflozin. Furthermore, these findings were generally consistent across the LVEF range. As previously reported, in patients admitted with WHF, sotagliflozin significantly reduced the composite of total cardiovascular death, hospitalization for heart failure, and urgent visit for heart failure by 33%.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LXRX:
- New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology
- Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
- Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
- Lexicon reports Q4 EPS (16c), consensus (13c)
- Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023